Manali Kamdar
Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma, Large B-Cell, Diffuse | 16 | 2023 | 93 | 6.550 |
Why?
| Lymphoma, Mantle-Cell | 7 | 2023 | 16 | 3.110 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 | 2023 | 59 | 2.970 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2023 | 1402 | 2.550 |
Why?
| Lymphoma, B-Cell | 5 | 2022 | 90 | 2.440 |
Why?
| Hematopoietic Stem Cell Transplantation | 9 | 2023 | 543 | 2.410 |
Why?
| Neoplasm Recurrence, Local | 14 | 2023 | 903 | 1.460 |
Why?
| Rituximab | 11 | 2023 | 161 | 1.440 |
Why?
| Lymphoma | 2 | 2022 | 185 | 1.370 |
Why?
| Immunoconjugates | 5 | 2023 | 90 | 1.350 |
Why?
| Neoplasms, Second Primary | 2 | 2020 | 91 | 1.330 |
Why?
| Immunotherapy, Adoptive | 8 | 2023 | 192 | 1.250 |
Why?
| Bendamustine Hydrochloride | 5 | 2022 | 11 | 1.090 |
Why?
| Antibodies, Monoclonal | 6 | 2023 | 1306 | 1.040 |
Why?
| Thrombocytopenia | 2 | 2023 | 188 | 0.940 |
Why?
| Antibodies, Bispecific | 1 | 2023 | 33 | 0.930 |
Why?
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 658 | 0.870 |
Why?
| Mediastinal Neoplasms | 3 | 2017 | 35 | 0.870 |
Why?
| Lymphoma, B-Cell, Marginal Zone | 2 | 2022 | 15 | 0.820 |
Why?
| Burkitt Lymphoma | 4 | 2021 | 54 | 0.770 |
Why?
| Neutropenia | 1 | 2021 | 134 | 0.770 |
Why?
| Positron-Emission Tomography | 2 | 2018 | 308 | 0.710 |
Why?
| Lymphoma, Follicular | 1 | 2019 | 31 | 0.710 |
Why?
| Hodgkin Disease | 4 | 2023 | 121 | 0.700 |
Why?
| Antigens, CD19 | 4 | 2023 | 108 | 0.690 |
Why?
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 71 | 0.690 |
Why?
| Bone Marrow | 3 | 2021 | 257 | 0.670 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 2017 | 201 | 0.660 |
Why?
| Lymphoproliferative Disorders | 1 | 2018 | 46 | 0.640 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2018 | 138 | 0.610 |
Why?
| Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 14 | 0.610 |
Why?
| Antineoplastic Agents | 5 | 2023 | 1990 | 0.610 |
Why?
| Prognosis | 12 | 2023 | 3563 | 0.600 |
Why?
| Humans | 57 | 2024 | 122796 | 0.560 |
Why?
| Transplantation, Autologous | 4 | 2023 | 189 | 0.520 |
Why?
| Cancer Survivors | 1 | 2019 | 225 | 0.520 |
Why?
| Adult | 28 | 2023 | 32385 | 0.480 |
Why?
| Cyclophosphamide | 5 | 2023 | 223 | 0.480 |
Why?
| Doxorubicin | 5 | 2023 | 304 | 0.450 |
Why?
| Vincristine | 4 | 2023 | 99 | 0.440 |
Why?
| Lymphoma, Non-Hodgkin | 2 | 2023 | 73 | 0.400 |
Why?
| Central Nervous System Neoplasms | 2 | 2022 | 129 | 0.360 |
Why?
| Retrospective Studies | 15 | 2023 | 13433 | 0.360 |
Why?
| Brain Neoplasms | 1 | 2017 | 1016 | 0.340 |
Why?
| Dexamethasone | 2 | 2022 | 323 | 0.340 |
Why?
| Middle Aged | 19 | 2023 | 28563 | 0.320 |
Why?
| Cord Blood Stem Cell Transplantation | 2 | 2020 | 96 | 0.320 |
Why?
| Graft vs Host Disease | 3 | 2020 | 219 | 0.320 |
Why?
| Kaplan-Meier Estimate | 6 | 2021 | 884 | 0.320 |
Why?
| Transplantation Conditioning | 5 | 2021 | 158 | 0.320 |
Why?
| Medical Oncology | 2 | 2020 | 231 | 0.300 |
Why?
| Aged | 16 | 2022 | 20495 | 0.300 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2023 | 165 | 0.290 |
Why?
| Cell- and Tissue-Based Therapy | 2 | 2023 | 55 | 0.280 |
Why?
| Aged, 80 and over | 11 | 2022 | 6845 | 0.270 |
Why?
| Proportional Hazards Models | 4 | 2023 | 1184 | 0.260 |
Why?
| Etoposide | 3 | 2023 | 149 | 0.260 |
Why?
| Standard of Care | 2 | 2022 | 67 | 0.260 |
Why?
| Male | 20 | 2022 | 59639 | 0.250 |
Why?
| Lymphoma, T-Cell, Peripheral | 1 | 2024 | 15 | 0.240 |
Why?
| Female | 20 | 2022 | 63629 | 0.240 |
Why?
| Tumor Lysis Syndrome | 1 | 2023 | 10 | 0.240 |
Why?
| Neoplasm Staging | 4 | 2020 | 1234 | 0.230 |
Why?
| Treatment Outcome | 12 | 2023 | 9692 | 0.220 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2022 | 85 | 0.200 |
Why?
| Hematologic Neoplasms | 1 | 2023 | 135 | 0.200 |
Why?
| Sulfonamides | 2 | 2022 | 455 | 0.200 |
Why?
| SEER Program | 2 | 2019 | 206 | 0.200 |
Why?
| Cisplatin | 1 | 2022 | 269 | 0.190 |
Why?
| Piperidines | 1 | 2022 | 169 | 0.190 |
Why?
| Methotrexate | 1 | 2022 | 227 | 0.190 |
Why?
| Immunotherapy | 2 | 2023 | 504 | 0.190 |
Why?
| Chlorambucil | 1 | 2020 | 8 | 0.190 |
Why?
| Disease Management | 3 | 2021 | 591 | 0.190 |
Why?
| Pyrazines | 1 | 2020 | 79 | 0.180 |
Why?
| Benzamides | 1 | 2020 | 175 | 0.180 |
Why?
| Risk Factors | 4 | 2023 | 9381 | 0.170 |
Why?
| Pyrimidines | 1 | 2022 | 388 | 0.170 |
Why?
| Pyrazoles | 1 | 2022 | 366 | 0.170 |
Why?
| Leukemia, Myeloid, Acute | 2 | 2023 | 534 | 0.170 |
Why?
| Antiviral Agents | 2 | 2021 | 670 | 0.170 |
Why?
| Neoplasm Grading | 1 | 2019 | 265 | 0.170 |
Why?
| Thiotepa | 1 | 2018 | 19 | 0.160 |
Why?
| Young Adult | 8 | 2022 | 11094 | 0.160 |
Why?
| Recurrence | 3 | 2018 | 998 | 0.160 |
Why?
| Leukemia, Hairy Cell | 1 | 2017 | 6 | 0.160 |
Why?
| Leukemia, B-Cell | 1 | 2017 | 11 | 0.160 |
Why?
| Herpes Zoster | 1 | 2022 | 334 | 0.160 |
Why?
| Combined Modality Therapy | 2 | 2018 | 1174 | 0.160 |
Why?
| Radiopharmaceuticals | 1 | 2018 | 196 | 0.150 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 268 | 0.150 |
Why?
| Prednisolone | 1 | 2017 | 76 | 0.150 |
Why?
| Symptom Assessment | 1 | 2018 | 124 | 0.150 |
Why?
| Follow-Up Studies | 4 | 2021 | 4768 | 0.150 |
Why?
| HIV Infections | 2 | 2021 | 2532 | 0.150 |
Why?
| ROC Curve | 1 | 2018 | 494 | 0.150 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2020 | 656 | 0.140 |
Why?
| Fatal Outcome | 1 | 2017 | 299 | 0.140 |
Why?
| Survivors | 1 | 2019 | 440 | 0.140 |
Why?
| Adolescent | 6 | 2022 | 18948 | 0.140 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 228 | 0.130 |
Why?
| Pneumonia, Viral | 1 | 2020 | 361 | 0.130 |
Why?
| Coronavirus Infections | 1 | 2020 | 349 | 0.130 |
Why?
| Disease-Free Survival | 3 | 2021 | 661 | 0.130 |
Why?
| T-Lymphocytes | 1 | 2023 | 1814 | 0.130 |
Why?
| United States | 9 | 2021 | 13272 | 0.130 |
Why?
| Societies, Medical | 1 | 2019 | 741 | 0.130 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2020 | 1260 | 0.120 |
Why?
| Survival Analysis | 4 | 2020 | 1325 | 0.120 |
Why?
| Immunosuppressive Agents | 1 | 2018 | 687 | 0.120 |
Why?
| Incidence | 1 | 2020 | 2527 | 0.110 |
Why?
| Healthcare Disparities | 1 | 2018 | 494 | 0.110 |
Why?
| Prednisone | 2 | 2023 | 234 | 0.110 |
Why?
| Cell Differentiation | 1 | 2019 | 1805 | 0.100 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 232 | 0.100 |
Why?
| Prevalence | 1 | 2018 | 2442 | 0.100 |
Why?
| Proto-Oncogene Proteins c-myc | 2 | 2023 | 122 | 0.100 |
Why?
| Delivery of Health Care | 1 | 2018 | 915 | 0.100 |
Why?
| Gene Rearrangement | 2 | 2021 | 141 | 0.080 |
Why?
| Infant, Newborn | 1 | 2019 | 5430 | 0.080 |
Why?
| Remission Induction | 2 | 2020 | 246 | 0.080 |
Why?
| Immunophenotyping | 2 | 2020 | 288 | 0.080 |
Why?
| Infant | 3 | 2019 | 8523 | 0.080 |
Why?
| Transplantation, Homologous | 2 | 2020 | 413 | 0.080 |
Why?
| Child, Preschool | 3 | 2019 | 9755 | 0.070 |
Why?
| Survival Rate | 2 | 2021 | 1810 | 0.070 |
Why?
| Clarithromycin | 2 | 1997 | 29 | 0.070 |
Why?
| Lung Neoplasms | 1 | 2017 | 2216 | 0.060 |
Why?
| Lactate Dehydrogenases | 1 | 2023 | 5 | 0.060 |
Why?
| Biomarkers, Tumor | 2 | 2020 | 1076 | 0.060 |
Why?
| North America | 1 | 2023 | 271 | 0.060 |
Why?
| Retreatment | 1 | 2022 | 72 | 0.050 |
Why?
| Stem Cell Transplantation | 1 | 2023 | 155 | 0.050 |
Why?
| Bleomycin | 1 | 2023 | 217 | 0.050 |
Why?
| Injections, Spinal | 1 | 2022 | 101 | 0.050 |
Why?
| Neoplasm, Residual | 1 | 2022 | 104 | 0.050 |
Why?
| Child | 3 | 2019 | 19561 | 0.050 |
Why?
| L-Lactate Dehydrogenase | 1 | 2021 | 114 | 0.050 |
Why?
| United Kingdom | 1 | 2021 | 260 | 0.050 |
Why?
| Cohort Studies | 2 | 2021 | 5294 | 0.050 |
Why?
| Immunization, Passive | 1 | 2020 | 82 | 0.050 |
Why?
| Australia | 1 | 2021 | 223 | 0.050 |
Why?
| Organizations, Nonprofit | 1 | 2020 | 20 | 0.050 |
Why?
| Europe | 1 | 2021 | 369 | 0.050 |
Why?
| Canada | 1 | 2021 | 355 | 0.040 |
Why?
| Central Nervous System | 1 | 2021 | 244 | 0.040 |
Why?
| Public Health Surveillance | 1 | 2018 | 63 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 988 | 0.040 |
Why?
| Myeloablative Agonists | 1 | 2018 | 22 | 0.040 |
Why?
| Vidarabine | 1 | 2018 | 27 | 0.040 |
Why?
| Fetal Blood | 1 | 2020 | 275 | 0.040 |
Why?
| Comorbidity | 1 | 2023 | 1600 | 0.040 |
Why?
| Lymphocytes | 1 | 2020 | 360 | 0.040 |
Why?
| Whole-Body Irradiation | 1 | 2018 | 72 | 0.040 |
Why?
| Mutation | 2 | 2020 | 3493 | 0.040 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2020 | 159 | 0.040 |
Why?
| Cytodiagnosis | 1 | 2017 | 29 | 0.040 |
Why?
| Immunoglobulin Heavy Chains | 1 | 2017 | 75 | 0.040 |
Why?
| Tonsillitis | 1 | 1997 | 7 | 0.040 |
Why?
| Chronic Disease | 1 | 2023 | 1645 | 0.040 |
Why?
| Betacoronavirus | 1 | 2020 | 265 | 0.040 |
Why?
| Penicillins | 1 | 1997 | 51 | 0.040 |
Why?
| Streptococcus pyogenes | 1 | 1997 | 37 | 0.040 |
Why?
| Pharyngitis | 1 | 1997 | 27 | 0.040 |
Why?
| Lymph Nodes | 1 | 2020 | 466 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 1531 | 0.040 |
Why?
| Anti-Inflammatory Agents | 1 | 2020 | 469 | 0.040 |
Why?
| Salvage Therapy | 1 | 2017 | 131 | 0.040 |
Why?
| Datasets as Topic | 1 | 2016 | 110 | 0.030 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 204 | 0.030 |
Why?
| Drug Resistance, Neoplasm | 1 | 2020 | 673 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2019 | 1727 | 0.030 |
Why?
| Streptococcal Infections | 1 | 1997 | 143 | 0.030 |
Why?
| Propensity Score | 1 | 2016 | 253 | 0.030 |
Why?
| Protein Kinase Inhibitors | 1 | 2020 | 833 | 0.030 |
Why?
| Radiotherapy | 1 | 2015 | 187 | 0.030 |
Why?
| Insurance Coverage | 1 | 2016 | 218 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2019 | 985 | 0.030 |
Why?
| Amoxicillin | 1 | 1993 | 19 | 0.030 |
Why?
| Diagnosis, Differential | 1 | 2017 | 1423 | 0.030 |
Why?
| Analysis of Variance | 1 | 2015 | 1329 | 0.030 |
Why?
| Pandemics | 1 | 2020 | 1401 | 0.030 |
Why?
| Gene Expression | 1 | 2017 | 1506 | 0.030 |
Why?
| Quality of Life | 1 | 2022 | 2457 | 0.030 |
Why?
| Otitis Media | 1 | 1993 | 149 | 0.020 |
Why?
| Prospective Studies | 1 | 2022 | 6704 | 0.020 |
Why?
| Registries | 1 | 2016 | 2020 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 1997 | 1562 | 0.020 |
Why?
| Time Factors | 1 | 2015 | 6682 | 0.020 |
Why?
| Suspensions | 1 | 1993 | 30 | 0.010 |
Why?
| Intestinal Absorption | 1 | 1993 | 106 | 0.010 |
Why?
| Single-Blind Method | 1 | 1993 | 275 | 0.010 |
Why?
| Family Practice | 1 | 1997 | 485 | 0.010 |
Why?
| Administration, Oral | 1 | 1993 | 786 | 0.010 |
Why?
| Acute Disease | 1 | 1993 | 984 | 0.010 |
Why?
| Body Weight | 1 | 1993 | 958 | 0.010 |
Why?
|
|
Kamdar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|